Ariad Pharmaceuticals Inc., of Cambridge, Mass., said the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA concluded its review of Iclusig (ponatinib) and has recommended that the drug continue to be used in Europe in accordance with its already approved indications for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia who are resistant to Sprycel (dasatinib.